Remove 2025 Remove Compounding Remove Dosage
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. June 9, 2025.

article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

Suggestions for providers featured in the guidelines include determining if opioids should take place, selecting appropriate dosages, determining prescription length and follow-up, and assessing and reducing risks of misuse, overdose, and opioid use disorder. Published 2025. Accessed August 1, 2025. Published July 31, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

On January 16, 2025, the FDA approved acalabrutinib (Calquence; AstraZeneca) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). January 16, 2025. Accessed May 14, 2025.

article thumbnail

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Pharmacy Times

Image credit: LASZLO | stock.adobe.com Gabrail et al presented data from a novel strategy involving continuous subcutaneous (SC) infusion of lenalidomide in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. Subscribe Now!

article thumbnail

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Pharmacy Times

The development of grade 2 or higher peripheral neuropathy has been shown to increase with cumulative treatment, thus necessitating close monitoring and possibly altering the dosage. Updated February 12, 2025. Accessed May 15, 2025. February 12, 2025. Accessed May 17, 2025. Accessed May 17, 2025. Pfizer Inc.

article thumbnail

Pharmacists Can Simplify the Vaccine Schedule

Pharmacy Times

Importantly, Novavax received FDA approval in May 2025 with restrictions: It is approved for individuals 65 years and older and patients aged 12 to 64 years with at least 1 health condition that puts them at risk for severe COVID-19. 5 This option should be available for patients for the 2025-2026 flu season.

article thumbnail

Daily CBD Use at Consumer-Level Doses May Elevate Liver Enzymes, FDA-Led Trial Shows

Pharmacy Times

Animal studies reveal dose-dependent hepatic responses to CBD, supporting the need for cautious monitoring even at consumer-relevant dosages. Pharmacists should review patient medication profiles, advise on appropriate dosage adjustments, and monitor for cumulative toxicity. of healthy adults, necessitating liver function monitoring.